PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies
Toronto, Ontario--(Newsfile Corp. - October 7, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a specialty pharmaceutical company advancing 3D-printed medicines, today announced the launch of the M3DICINES™ National Network Program (the "Network Program"). The program will build a national network of qualified sites that make personalized medicines on CraftMake™ pharmaceutical 3D printers, supported by PharmaTher's M3DICINES™ platform. The network...
2026-10-07 8:00 AM EDT
PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES
Highlights M3DICINES™ 3D-printed medicines platform. One platform for PharmaTher's proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label products, formulation licensing and clinical trial supply. Commercial launch of M3DICINES™. Initial orders of the CraftMake™ pharmaceutical 3D printer, the platform's entry point, are planned for Q4 2026. Near-term products. First proprietary 503A peptide products are planned for Q4 2026, followed by a ketamine...
2026-10-05 8:00 AM EDT
PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform
Highlights PharmaTher is now the exclusive distributor in North America of Craft Health's CraftMake™ 3D printers, CraftControl™ software, CraftBlends™ printable formulations, consumables, and service. Exclusivity covers every key customer segment: compounding pharmacies (503A and 503B), telehealth and digital health companies, CDMOs, hospitals, academic, research, and government institutions, and pharmaceutical, biotechnology, and healthcare companies. PharmaTher estimates more than 10,000...
2026-10-01 8:00 AM EDT
PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)
Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a life sciences company focused on personalized medicines, today announced that PERSONALIZ3D™, the Company's integrated telehealth and pharmaceutical 3D printing platform for personalized medicines and peptides, is advancing toward commercialization through a collaboration agre
2026-08-18 8:00 AM EDT
PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing
Toronto, Ontario--(Newsfile Corp. - August 11, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a life sciences company focused on personalized medicines, today announced the establishment of PERSONALIZ3D™, an integrated ecosystem that will combine telehealth, pharmaceutical 3D printing, and pharmacy fulfillment to support the delivery of personalized medicines. PERSONALIZ3D™ expands PharmaTher's previously announced Personaliz3D Peptides™...
2026-08-11 8:00 AM EDT
PharmaTher Collaborates with Craft Health to Evaluate CraftMake(TM) GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptides
Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized medicines, announced today a collaboration with Craft Health Pte. Ltd. ("Craft Health") to evaluate Craft Health's CraftMake™ GMP-ready pharmaceutical 3D printing platform for PharmaTher's Personaliz3D Peptides™ partner ecosystem. The collaboration will focus on developing novel peptide formulations...
2026-07-29 8:00 AM EDT
PharmaTher Launches Personaliz3D Peptides(TM) to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations
Toronto, Ontario--(Newsfile Corp. - July 27, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized medicines, announced today the launch of Personaliz3D Peptides™, a new division focused on developing and commercializing personalized peptide products and protocols using 3D printing and ar
2026-07-27 8:00 AM EDT
PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval
Toronto, Ontario--(Newsfile Corp. - July 21, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized medicines for peptides and psychedelics, today announced a collaboration with Curtis W. Cassidy, M.
2026-07-21 8:00 AM EDT
PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics
Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized medicines, today provided a corporate update outlining its strategic focus on personalized medicines, specifically peptides and psychedelics. PharmaTher believes peptides and psychedelics are gaining strong momentum and plans to capitalize on this opportunity using its MEDBOTX™ 3D-printing platform...
2026-07-15 8:00 AM EDT
PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines
Toronto, Ontario--(Newsfile Corp. - May 27, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a pharmatech company focused on enabling personalized medicine through robotic 3D printing, today announced that it is strategically evolving its platform focus from PatchPrint™ 3D printer to MEDBOTX™, the Company
2026-05-27 8:00 AM EDT
PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, today announced that Sairiyo Therapeutics Inc. ("Sairiyo"), a company 49% owned by PharmaTher and 51% owned by PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF), is pursuing its strategic plans to focus on the clinical development of its patented enteric-coated oral Cepharanthine ("PD-001") as a potential therapeutic candidate...
2026-05-13 10:11 AM EDT
PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness
Toronto, Ontario--(Newsfile Corp. - April 21, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, today announced that it believes the recent U.S. executive order, "Accelerating Medical Treatments for Serious Mental Illness," signed on April 18, 2026, may help create a more supportive political and regulatory backdrop for innovative ketamine-based programs, particularly where severe unmet need, depression,...
2026-04-21 8:00 AM EDT
PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides
Toronto, Ontario--(Newsfile Corp. - April 20, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on microneedle patch technologies, believes it is well-positioned to benefit from two major U.S. regulatory developments: growing federal support for psychedelic medicine and advancing efforts to restore broader compounding access for select therapeutic peptides. Two major U.S. fed
2026-04-20 8:00 AM EDT
PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery
Toronto, Ontario--(Newsfile Corp. - April 16, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on microneedle patch technologies and peptide-enabled product opportunities, today expressed support for recent U.S. initiatives led by U.S. Health and Human Services Secretary Robert F. Kennedy Jr. and the U.S. Food and Drug Administration (FDA) to revisit the regulatory treatment of select therapeutic peptides....
2026-04-16 8:00 AM EDT
PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology
Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, announced it has submitted U.S. provisional patent application No. 64/034,315 to the United States Patent and Trademark Office, titled "Stabilized Peptide Compositions for Microneedle and Transdermal Delivery." The patent filing covers formulation technologies designed to help protect peptides from degradation during...
2026-04-13 8:00 AM EDT
PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches
Toronto, Ontario--(Newsfile Corp. - March 26, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, announced it submitted a provisional patent application to USPTO for PatchPrint™, its Automated Tabletop Microneedle Patch 3D Printer. The application is titled "Automated Tabletop Microneedle Patch Printer with Integrated Demolding, Packaging, and Multi-Product Cargo-Adaptive Processing" (Applica
2026-03-26 8:00 AM EDT
PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market
Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the therapeutic potential of psychedelics and peptides, today announced a strategic initiative to expand its PharmaPatch™ microneedle patch platform into select therapeutic peptides for the U.S. market, building on the Company's ketamine and psychedelics patch development achievements and its recent...
2026-03-03 8:00 AM EST
PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success
Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a specialty pharmaceutical company, today announced a new strategic initiative to pursue Health Canada approval for generic semaglutide in Canada and, subject to regulatory approval, its commercialization. Semaglutide is the active ingredient in Ozempic® and Wegovy®. The initiative builds on PharmaTher's demonstrated regulatory and partnering execution,...
2026-02-02 9:27 AM EST
PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs
Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the therapeutic potential of ketamine, psychedelics, and GLP-1 drugs for neuropsychiatric and obesity disorders, today announced a new strategic initiative to expand its PharmaPatch™ microneedle patch platform into GLP-1 therapies for the potential treatment of obesity. PharmaTher's decision to...
2026-01-14 8:00 AM EST
PharmaTher CEO Publishes Letter to Shareholders
Toronto, Ontario--(Newsfile Corp. - January 2, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher") today announced that CEO Fabio Chianelli has published a letter to shareholders. Dear Shareholders, With 2025 complete, I want to thank you for your continued support of PharmaTher. This past year marked a shift from ambitious development to concrete validation, setting the stage for what I believe will be a value-unlocking year ahead. PharmaTher's...
2026-01-02 8:00 AM EST